Leadership
Executive Team
Sanjay Keswani, MBBS, FRCP
Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, a...
Read more >>
Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of successful Nasdaq IPO (Annexon), acquisition (MiroBio by Gliead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships. Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew’s Hospital (UK’s oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).
Prof. Michal Schwartz
A world-renowned expert in Neuroimmunology who pioneered the field of nervous system repair, protection, and maintenance by the immune system. Schwartz is a professor of Neuroimmunology at the Weizmann Institute of Science (WIS). She was the first to suggest, against the prevailing dogma at the time, that circulating immune cells are e...
Read more >>
A world-renowned expert in Neuroimmunology who pioneered the field of nervous system repair, protection, and maintenance by the immune system. Schwartz is a professor of Neuroimmunology at the Weizmann Institute of Science (WIS). She was the first to suggest, against the prevailing dogma at the time, that circulating immune cells are essential for supporting life-long functional brain plasticity in health and disease, and should be harnessed to help fighting brain pathologies. These results led to the paradigm-shifting approach of developing an immunotherapy to combat neurodegenerative diseases. Her scientific publications have been extremely influential, as reflected by their high citation scores. Schwartz has received numerous national and international awards, and served as president of the International Society of Neuroimmunology (2016-2018).
Roee Hevrony
Prior to joining ImmunoBrain in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. Roee holds a bachelor’s degree in Economics from Columbia University (magna cum laude) and an MBA from the Wharton School of the Unive...
Read more >>
Prior to joining ImmunoBrain in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. Roee holds a bachelor’s degree in Economics from Columbia University (magna cum laude) and an MBA from the Wharton School of the University of Pennsylvania.
Tommaso Croese, MD
Tommaso is a Neurologist with extensive experience in neuroimmunology, focusing on the role of immune cells in neurological disorders such as Multiple Sclerosis and Alzheimer’s Disease. His expertise is backed by over 10 years in preclinical model research, shaping a deeper understanding of these diseases. After completing his residenc...
Read more >>
Tommaso is a Neurologist with extensive experience in neuroimmunology, focusing on the role of immune cells in neurological disorders such as Multiple Sclerosis and Alzheimer’s Disease. His expertise is backed by over 10 years in preclinical model research, shaping a deeper understanding of these diseases. After completing his residency in neurology at San Raffaele Hospital in Milan, Tommaso pursued his PhD at the Weizmann Institute of Science, further enriching his clinical and research capabilities. During his PhD, he authored numerous scientific papers, underscoring the interaction between the brain and the immune system.
Sharona Raveh, Ph.D., MBA
Over 20 years of experience in global biopharmaceutical companies, running operations and R&D teams, leading CMC and CMO activities from early phase development through commercial production. Sharona served as Senior Director, Head of Bio-Analytical Development, CMC Biosimilars for Teva Pharmaceuticals. Prior to that Sharona was D...
Read more >>
Over 20 years of experience in global biopharmaceutical companies, running operations and R&D teams, leading CMC and CMO activities from early phase development through commercial production. Sharona served as Senior Director, Head of Bio-Analytical Development, CMC Biosimilars for Teva Pharmaceuticals. Prior to that Sharona was Director of Analytical Development and CMC project manager in BTG, Ferring. Sharona holds an M.SC. from Ben-Gurion University, Ph.D from PARIS VI University and Pasteur Institute in protein engineering, structure and function and MBA in management and business psychology from The college of management.
Kuti Baruch, Ph.D.
Neuroimmunologist with over 15 years of biomedical experience in developing therapeutic approaches to neurodegenerative conditions. Kuti joined ImmunoBrain when the company was founded, following licensing of the technology that was developed at the Weizmann Institute of Science in his Ph.D. and Postdoctoral studies at Prof. Schwartz’s...
Read more >>
Neuroimmunologist with over 15 years of biomedical experience in developing therapeutic approaches to neurodegenerative conditions. Kuti joined ImmunoBrain when the company was founded, following licensing of the technology that was developed at the Weizmann Institute of Science in his Ph.D. and Postdoctoral studies at Prof. Schwartz’s laboratory. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.
Alex Kertser, Ph.D.
Neuroimmunologist with over 10 years of experience in pre-clinical project management, assay development and in-depth understanding of experimental animal models. Dr. Kertser holds a B.Sc in biology and chemistry from the Hebrew University, and both M.Sc and Ph.D in Neuroimmunology from the Weizmann institute of Science.
Neuroimmunologist with over 10 years of experience in pre-clinical project management, assay development and in-depth understanding of experimental animal models. Dr. Kertser holds a B.Sc in biology and chemistry from the Hebrew University, and both M.Sc and Ph.D in Neuroimmunology from the Weizmann institute of Science.
Dalia Bracha, RN, BSN, MPA
An experienced clinical Project Manager with more than 22 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals, CRO and emerging biotech companies.
An experienced clinical Project Manager with more than 22 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals, CRO and emerging biotech companies.
Iris Tavor
An experienced regulatory and quality affairs manager, with over 20 years of hands-on experience in clinical development of innovative medicinal products across a number of therapeutic areas. In-depth understanding of regulatory requirements for drugs and biologics from early phase development through to phase 3 clinical trials worldwi...
Read more >>
An experienced regulatory and quality affairs manager, with over 20 years of hands-on experience in clinical development of innovative medicinal products across a number of therapeutic areas. In-depth understanding of regulatory requirements for drugs and biologics from early phase development through to phase 3 clinical trials worldwide.
Our Advisory Board
Dr. Jan Egebjerg, Ph.D
SVP Grants and Prizes Lundbeckfoundation. Previously Senior Director of Neurodegeneration at Janssen since 2018. Previously he was Divisional Director for Neurodegeneration at H. Lundbeck A/S and ass. professor at Dept for Molecular Biology, University of Aarhus.
SVP Grants and Prizes Lundbeckfoundation. Previously Senior Director of Neurodegeneration at Janssen since 2018. Previously he was Divisional Director for Neurodegeneration at H. Lundbeck A/S and ass. professor at Dept for Molecular Biology, University of Aarhus.
Lon Schneider, MD
Professor of Psychiatry and Behavioral Sciences. Director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health)....
Read more >>
Professor of Psychiatry and Behavioral Sciences. Director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health).
Michael Davidson, MD
Professor of Psychiatry at the Sackler School of Medicine Tel Aviv and Mount Sinai School of Medicine NYC . Currently Executive President of the Alzheimer Center in Tel Aviv, an organization providing inpatient and community care to several hundred demented elderly.
Professor of Psychiatry at the Sackler School of Medicine Tel Aviv and Mount Sinai School of Medicine NYC . Currently Executive President of the Alzheimer Center in Tel Aviv, an organization providing inpatient and community care to several hundred demented elderly.
Paul Aisen, MD
Professor of Neurology; Director, Alzheimer’s Therapeutic Research Institute, University of Southern California.
Professor of Neurology; Director, Alzheimer’s Therapeutic Research Institute, University of Southern California.
Board of Directors
Dr. Avraham Kadar
Avraham Kadar, MD, is a physician-scientist, entrepreneur, investor, and philanthropist. He is the founding chief executive officer of BrainPOP, a pioneering digital education company that has engaged, inspired, and impac...
Read more >>
Avraham Kadar, MD, is a physician-scientist, entrepreneur, investor, and philanthropist. He is the founding chief executive officer of BrainPOP, a pioneering digital education company that has engaged, inspired, and impacted millions of students across the world for more than two and a half decades. Dr. Kadar continues to serve on the BrainPOP board of directors following the company’s acquisition in 2022 by KIRKBI, the family-owned holding and investment company of the LEGO brand—its first acquisition in digital learning. A pediatrician and immunologist by training, Dr. Kadar began his career at the National Institutes of Health (NIH), where he was a fellow in the laboratory of clinical investigation at the height of the AIDS epidemic.
Mr. Nathan Hevrony
Founder and Executive Chairman of ImmunoBrain. An entrepreneur and private equity investor with 40 years experience in financing and M&A in industrial and biotechnology companies. Serves as a director and trustee in public and private enterprises.
Founder and Executive Chairman of ImmunoBrain. An entrepreneur and private equity investor with 40 years experience in financing and M&A in industrial and biotechnology companies. Serves as a director and trustee in public and private enterprises.
Sanjay Keswani, MBBS, FRCP
Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, a...
Read more >>
Dr Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech. He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom. Sanjay was Senior Vice President of R&D at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas including Immunology, Neuroscience, Rare Diseases, Fibrosis and Virology. He has held CEO and CMO positions in biotech with experience of successful Nasdaq IPO (Annexon), acquisition (MiroBio by Gliead), venture fundraising (Series A, B, D rounds), and multiple industry partnerships. Sanjay has been instrumental in the development of several approved medicines, including Risdiplam, Emgality, Faricimab, Cymbalta, Aimovig and Deucravacitnib. Sanjay completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins. He graduated in medicine at St. Bartholomew’s Hospital (UK’s oldest hospital founded in 1123) and holds a First Class honors BSc degree from St. Mary’s Hospital, London in Pathology & Basic Medical Sciences (Immunology).
Rochelle Walensky, MD, MPH
Dr. Walensky, a professor of medicine at Harvard Medical School, spent her career in infectious disease clinical practice, research, and policy, with a particular focus on the promotion of global access to HIV prevention, screening, and care. She served as the 19th director of the U.S. Centers for Disease Control and Prevention as well...
Read more >>
Dr. Walensky, a professor of medicine at Harvard Medical School, spent her career in infectious disease clinical practice, research, and policy, with a particular focus on the promotion of global access to HIV prevention, screening, and care. She served as the 19th director of the U.S. Centers for Disease Control and Prevention as well as chief of the Division of Infectious Diseases at Massachusetts General Hospital. Dr. Walensky also serves as chair of scientific council at the Global Brain Care Coalition.
Mr. Jay Kranzler
Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. Most recently served as Global Head - External R&D Innovation - Neuroscience, Pain, and Sensory Disorders for Pfizer.
Founder, CEO, Board Member, and Advisor to leading life science companies for over 30 years. Most recently served as Global Head - External R&D Innovation - Neuroscience, Pain, and Sensory Disorders for Pfizer.
